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Summary
Activating mutations in AVPR2 are associated with nephrogenic syndrome of inappropriate antidiuresis (NSIAD). 
NSIAD causes hyponatremia, decreased serum osmolality and clinical symptoms, which may present from birth or in 
infancy and include hypotonia, irritability, vomiting and/or seizures. Symptoms in later life are often less specific and 
include malaise, dizziness, confusion, tiredness and headache. NSIAD is a rare X-linked condition, which is associated 
with a variable phenotype in males, of whom some present in infancy but others do not become symptomatic 
until adulthood, or occasionally, never. Female carriers may present with episodes of hyponatremia, usually found 
incidentally. Literature in this field is limited; namely, two clinical reports describing a female proband, both 
diagnosed in infancy. We describe, for the first time, the case of an adult female proband with NSIAD, who had 
longstanding associated symptoms of tiredness, headache, temporary memory loss and mood changes as well as 
hyponatremia and decreased serum osmolality. A water load test demonstrated an inability to dilute urine and gene 
sequencing confirmed a recurrent activating mutation in AVPR2. The variant was inherited from the proband’s mother 
who had had longstanding episodes of transient asymptomatic hyponatremia. This is the third report of a female 
proband with NSIAD and is the first female reported who sought medical treatment for chronic symptoms from 
adulthood. This case acts as a reminder of the importance of considering NSIAD as a diagnosis in females of all ages 
with unexplained hyponatremia.
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Learning points:
 • Activating mutations in the AVPR2 gene are associated with the rare X-linked condition nephrogenic syndrome of 
inappropriate antidiuresis.
 • NSIAD is associated with hyponatremia, decreased serum osmolality and inappropriately increased urinary 
osmolality. Early clinical symptoms in infancy include hypotonia, irritability, vomiting and/or seizures. Symptoms in 
later life include malaise, dizziness, confusion, tiredness and headache.
 • NSIAD should be considered in female, as well as male, patients who present with unexplained hyponatremia and 
decreased serum osmolality. Family history may reveal relevant symptoms or biochemical features in other family 
members. However, family history may not always be informative due to the variable nature of the condition or if 
the proband has a de novo pathogenic variant.
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Background
Nephrogenic syndrome of inappropriate antidiuresis 
(NSIAD, OMIM 300539) is associated with gain-of-
function pathogenic variants in AVPR2, which encodes 
the vasopressin V2 receptor (1). Activating mutations 
cause constitutive activation of the vasopressin receptor 
resulting in antidiuresis and therefore cause the 
biochemical and clinical features of NSIAD. In contrast, 
loss-of-function mutations in AVPR2 cause X-linked 
congenital nephrogenic diabetes insipidus (2).
NSIAD has been traditionally described as an X-linked 
recessive condition with index cases usually being 
male but with marked interfamilial and intrafamilial 
heterogeneity regarding the age of diagnosis and severity 
of disorder. To date, carrier females have most commonly 
been asymptomatic and identified during familial cascade 
screening. The two exceptions have been clinical reports 
of females who were both diagnosed with NSIAD in 
infancy (3, 4). However, a female proband presenting with 
chronic symptoms in adulthood has not been previously 
described until now. We describe the clinical features 
of our patient and describe relevant investigations and 
management. We outline the diagnostic utility of a water 
load test for NSIAD prior to molecular sequencing of 
AVPR2. Furthermore, we demonstrate that measurement 
of co-peptin levels can be used as an alternative to direct 
AVP measurement during the water load test.
Case presentation
Our patient was an only child and was born to non-
consanguineous white British parents. Her mother had 
had difficulty conceiving, possibly due to a congenital 
uterine malformation and underwent hysterectomy after 
our patient was born. The proband was born at term after 
a normal pregnancy. Her development and early medical 
history were unremarkable. She had glandular fever at 
the age of 16  years and described feeling continually 
unwell from that time. Between the ages of 16 and 
30 years she regularly experienced symptoms of nausea, 
headache and malaise, which were significant enough 
for her to attend the local hospital emergency room. 
On these occasions, she was found to be hyponatremic 
(serum sodium around 125 mmol/L) with normal serum 
potassium and bicarbonate levels. Clinical management 
included hospital admission and fluid restriction. This 
resulted in normalization of her serum sodium levels and 
resolution of her clinical symptoms. She also reported 
other symptoms, related to the episodes of hyponatremia, 
and these included tiredness, occasional memory loss, 
mood changes and depressive symptoms. There was no 
history of seizures.
In her twenties, she was given a provisional 
diagnosis of SIADH based on the biochemical profile of 
persistent hyponatremia with plasma serum sodium of 
125–132 mmol/L (reference range 133–146 mmol/L) 
associated with a low serum osmolality of around 
270 mosmol/kg (reference range 275–295 mosmol/kg) 
while euvolemic. Management included fluid restriction 
and sodium chloride supplements, which had variable 
effect, possibly due to tolerability. Due to lack of consistent 
improvement, she underwent a trial of demeclocycline, 
but again with limited sustained benefit.
Additionally aged 16 years, she was investigated 
for primary ovarian insufficiency but no cause was 
identified. Genetic testing failed to identify either a 
Fragile X syndrome premutation or any chromosomal 
abnormalities. She also underwent investigations for 
autoimmune disorders, which were negative. The 
premature ovarian failure resulted in sub-fertility, and she 
later adopted two children. She underwent investigations 
for chronic fatigue syndrome and was diagnosed with 
fibromyalgia.
Investigation
She was further investigated as no underlying cause had 
been found for her symptoms and biochemical profile. At 
this time, she remained euvolemic, with a plasma sodium 
of 133–136 mmol/L, but urine osmolality was raised 
(626 mosmol/kg). Adrenocortical and thyroid function 
 • A water load test with measurement of AVP may be informative in distinguishing NSIAD from SIADH. 
Measurement of co-peptin levels may be considered, in substitution for direct measurement of AVP.
 • Patients with NSIAD should be counseled about appropriate daily fluid volume intake. Potential episodes of fluid 
overload should be avoided.
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tests and an acute intermittent porphyria screen were 
normal. She was taking no medication which could be 
responsible for her symptoms. Cross-sectional imaging 
of the head, chest and abdomen did not identify an 
infectious or neoplastic cause for SIADH and an octreotide 
isotope scan was also normal.
A water load test was therefore considered to determine 
if the hyponatremia was due to an inability to dilute urine 
in the presence of a relative excess of free water (Table 1). 
This test was carried out in a controlled environment and 
under direct supervision, given the risk of exacerbating 
hyponatremia associated with this test. This investigation 
demonstrated a marked inability of the patient to excrete 
a free water load (40% of a 20 mL/kg oral fluid load by 
240 min post ingestion). Normal subjects excrete 78–82% 
of the water load in 4 h. There was onset of hyponatremia 
at 128 mmol/L and a persistently elevated urine osmolality 
during the test. However, serum co-peptin, a peptide 
released together with AVP, was undetectable throughout 
the test (<1.3 pmol/L), which indicated that our patient 
did not have SIADH. The water load test was therefore 
important in establishing that NSIAD was the most likely 
diagnosis in our patient. The value of the water load test 
in the diagnosis of NSIAD is described by Ranchin and 
coworkers (5).
To confirm the diagnosis, next-generation sequencing 
(NGS) was carried out with the Illumina TruSight One 
sequencing panel using the MiSeq Illumina NGS platform. 
Reads were aligned; variants were called and initial pre-
filtering was carried out using an in-house bioinformatics 
pipeline. This pipeline filtered the data to only show 
AVPR2 variants. Variants with a population frequency 
greater than 1 in 50 were automatically deemed as 
insignificant.
Variant interpretation of the remaining variants was 
carried out using the Alamut Visual software. All variants 
of class 4 or above, according to the current ACMG 
guidelines, were then confirmed by Sanger sequencing 
(6). The recurrent mutation c.409C > T, p.(Arg137 Cys) was 
identified in AVPR2, confirming the diagnosis of NSIAD. 
X-linked inactivation studies were requested and showed 
an unskewed pattern in blood.
The pathogenic variant was found to be maternally 
inherited. On review of the medical records, our 
patient’s mother had experienced recurrent episodes of 
hyponatremia during illness, for example, after an episode 
of shingles, but also on routine medical review, with the 
lowest serum sodium recorded at 130 mmol/L. She also 
had a history of lupus and Hashimoto’s thyroiditis but 
did not display any symptoms of NSIAD. Her parents were Ta
b
le
 1
 
Th
e 
re
su
lt
s 
o
f 
th
e 
w
at
er
 lo
ad
 t
es
t 
fo
r 
o
u
r 
p
at
ie
n
t 
u
si
n
g
 a
 p
ro
to
co
l a
d
ap
te
d
 f
ro
m
 a
 p
re
vi
o
u
s 
p
u
b
lic
at
io
n
 (
10
).
 (m
in
)
U
ri
n
e
 
o
u
tp
u
t 
(m
L)
V
e
n
o
u
s 
g
a
s 
N
a
 (
m
m
o
l/L
)
La
b
 N
a
 
(m
m
o
l/L
)
 
K
 (
m
m
o
l/L
)
 
G
lu
 (
m
m
o
l/L
)
 
U
re
a
 (
m
m
o
l/L
)
 
C
re
a
ti
n
in
e
 (
µ
m
o
l/L
)
S
e
ru
m
 o
sm
o
la
li
ty
 
(m
o
sm
o
l/k
g
)
U
ri
n
e
 o
sm
o
la
li
ty
 
(m
o
sm
o
l/k
g
)
C
o
-p
e
p
ti
n
 
(p
m
o
l/L
)
0
13
6.
0
13
4
4.
4
5.
1
5.
9
48
28
0
71
0
<
1.
3
60
30
0
13
1.
1
12
8
4.
9
4.
3
43
27
2
12
0
30
0
12
9.
1
12
8
4.
9
4.
2
43
26
4
<
1.
3
18
0
20
0
12
8.
1
12
9
3.
8
4.
8
3.
9
37
26
6
24
0
40
13
1.
1
12
8
3.
8
4.
6
3.
9
37
26
2
<
1.
3
36
0
10
0
13
0.
5
12
8
3.
9
4.
6
3.
9
39
26
7
49
5
09
:0
0 
h
 
fo
llo
w
in
g
 
m
o
rn
in
g
N
/A
 
 
N
/A
 
 
13
4  
4.
4  
4.
6  
5.
9  
48
 
 
28
7  
60
9  
  
A
 w
at
er
 lo
ad
 b
as
ed
 o
n
 t
h
e 
fo
llo
w
in
g
 c
al
cu
la
ti
o
n
 (
20
 m
L/
kg
 =
 1
50
8 
m
L)
 w
as
 p
er
fo
rm
ed
. W
it
h
in
 6
0 
m
in
 o
f 
th
e 
w
at
er
 lo
ad
 c
o
n
su
m
p
ti
o
n
, s
er
u
m
 s
o
d
iu
m
 d
ro
p
p
ed
 t
o
 1
28
 m
m
o
l/L
 f
ro
m
 1
34
 m
m
o
l/L
 b
u
t 
co
-p
ep
ti
n
 r
em
ai
n
ed
 s
u
p
p
re
ss
ed
 c
o
n
si
st
en
t 
w
it
h
 a
 d
ia
g
n
o
si
s 
o
f 
n
ep
h
ro
g
en
ic
 S
IA
D
. F
u
rt
h
er
m
o
re
, t
h
e 
p
at
ie
n
t 
fa
ile
d
 t
o
 e
xc
re
te
 t
h
e 
ex
p
ec
te
d
 7
0–
80
%
 (
10
56
–1
20
6 
m
L)
 o
f 
th
e 
w
at
er
 lo
ad
 v
o
lu
m
e 
w
it
h
in
 
fo
u
r 
h
o
u
rs
, a
s 
in
d
ic
at
ed
 b
y 
th
e 
u
ri
n
e 
o
u
tp
u
t 
(8
40
 m
L 
in
 4
 h
).
J Hague and others Adult female with symptomatic 
NSIAD
ID: 17-0139; February 2018
DOI: 10.1530/EDM-17-0139
http://www.edmcasereports.com 4
deceased, and her two brothers (one deceased) did not 
have any relevant symptoms. However, predictive genetic 
testing has been offered to the wider family.
Treatment
Our patient is now asymptomatic on daily fluid restriction 
of 1–1.5 L. This recommended volume of fluid was based 
on the lowest daily fluid volume our patient felt she could 
tolerate, while ensuring that her sodium levels remain 
just under or within the normal range (usually between 
132 and 135 mmol/L).
Outcome and follow-up
Our patient has been followed up for a further 12 months, 
since she received her genetic diagnosis. She remains 
asymptomatic on fluid restriction.
Discussion
NSIAD was first described in 2005 in two infant boys (1). 
Since then, around 30 cases have been reported. Several 
activating mutations have been described but our patient’s 
mutation, R137C, causing an arginine to cysteine change, 
is the most commonly reported to date.
NSIAD is inherited in an X-linked manner and the 
majority of index patients have been males. However, 
there have been several reports where females with 
NSIAD have been identified on cascade screening (3, 7, 
8). Asymptomatic carrier females have been reported 
who have normal plasma sodium and osmolality (1). In 
contrast, other asymptomatic female carriers have had 
documented episodes of hyponatremia and/or when 
investigated with a water load test, have had impaired 
ability to dilute urine (3, 7, 8). Decaux and coworkers 
described a female who had molecularly-confirmed 
NSIAD but did not have episodes of hyponatremia or 
an abnormal water load test. X-inactivation studies were 
compatible with preferential inactivation of her mutated 
allele (7). Gupta and coworkers reported a male infant and 
his mother who both had NSIAD. The mother had learned 
to avoid excess fluid consumption because of associated 
malaise. Both family members had a subnormal ability to 
excrete a water load, with the mother also demonstrating 
a heightened sense of thirst at low serum osmolalities (8). 
Ranchin and coworkers described the value of the water 
load test in helping to diagnose NSIAD and distinguish 
it from cases of SIADH. The paper describes the results 
of the water load test that would be expected in both 
hemizygous males and heterozygous females with an 
activating AVPR2 pathogenic variant (5).
There have been two reports of female probands 
who both presented in infancy (3, 4). A 1-year-old girl 
was referred for persistent hyponatremia, which was 
first noted incidentally during an intercurrent infection. 
She had global developmental delay, although it is 
unclear if this was related to her diagnosis of NSIAD. Her 
mother reported a strong aversion to fluids, because she 
subsequently would experience headaches, which could 
be relieved only by eating salty foods. She passed urine 
only once or twice a day. The maternal grandmother 
reported similar symptoms. Genetic studies confirmed 
NSIAD in all family members (3). In the second case, 
the infant presented with diarrhea and poor feeding at 
23 days of age. She was found to have mild hypertension 
and continuing episodes of hyponatremia. Her brother 
was known to have NSIAD and the diagnosis was also 
confirmed in her, with chromosome inactivation studies 
showing an unskewed X-inactivation pattern (4).
Identifying patients with NSIAD is important for 
symptom control as well as long-term management of 
fluid restriction. It is especially important to consider the 
diagnosis in infancy if a child presents with irritability, 
vomiting and/or seizures and a biochemical picture of 
SIADH, as SIADH is rare in pediatric patients and NSIAD is 
more likely, especially if the patient has low or undetectable 
AVP levels. Immediate management includes fluid 
restriction and possibly medication, including the osmotic 
agent urea and inverse agonists for specific variants, e.g. 
p.(Phe299Val) and p.(lle130Asn) (9, 10). It is important 
to counsel patients on appropriate daily fluid volume 
intake and to ensure that episodes of fluid overload can 
be avoided, such as increased fluid intake in summertime 
or during sports activities or excessive intravenous fluid 
administration during hospital admissions.
In conclusion, we propose that NSIAD should be 
considered as a diagnosis in female, as well as male, 
patients who present with unexplained hyponatremia 
and decreased serum osmolality. A water load test may 
be informative, and measurement of co-peptin levels may 
be considered, in substitution for direct measurement of 
AVP, to aid diagnosis and guide diagnostic sequencing of 
AVPR2. In families with a known history of NSIAD, we 
would recommend that both females and males, from 
birth onwards, should be offered genetic testing for the 
familial variant and, if positive, referred to endocrinology 
for long-term management. Due to the increasing 
availability of genetic testing, confirmation of diagnosis 
is becoming easier. We conclude that, as with many other 
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X-linked disorders, the concept of a truly recessive X-linked 
inheritance is becoming blurred. This is explained by the 
random and mosaic nature of X-inactivation in females.
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